000			a
999			_c16223 _d16223
003			OSt
005			20220204122000.0
008			220204b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_98813 _aMorsy, Mohamed Aly
245			_aProtection of hesperidin against methotrexate- induced nephrotoxicity may be mediated by Nrf2/HO-1 pathway
250			_aVol.55(4), Oct-Dec
260			_aKarnataka _bAssociation of Pharmaceutical Teachers of India (APTI) _c2021
300			_a1066-1073p.
520			_aBackground: Methotrexate (MTX), a successfully used chemotherapeutic in the treatment of various malignancies and autoimmune diseases, might cause severe nephrotoxicity. Here, we aimed at investigating possible nephroprotective effects of hesperidin (HES), a flavanone present in citrus fruits, against MTX-induced toxicity. Methods: Rats were divided into control, HES, MTX, and MTX/HES groups, where HES was administered in a dose of 100 mg/kg/day orally for 8 days and MTX in a single i.p. dose of 20 mg/kg on day 5 of the experiment. Results: Pretreatment with HES significantly improved MTXinduced deteriorated kidney function and structure, as well as reversed MTX effects on renal tumor necrosis factor (TNF)-α level and caspase 3 expression. MTX upregulated renal breast cancer resistance protein (BCRP); an efflux transporter that extrudes MTX from the kidney. Unfortunately, MTX/HES did not show a further increase in BCRP expression but rather showed downregulation. MTX also caused downregulation of renal nuclear factor erythroid 2-related factor 2 (Nrf2) and hemeoxygenase-1 (HO-1) expressions, whereas HES reversed the MTX effect and upregulated renal Nrf2/HO-1. Conclusion: HES conferred protection against MTX-mediated nephrotoxicity, at least in part via anti-inflammatory and anti-apoptotic mechanisms. Nrf2/HO-1 pathway, but not BCRP, may have a role in HES-induced nephroprotection against MTX toxicity.
650		0	_94639 _aPHARMACEUTICS
700			_915861 _a El-Sheikh, Azza Ali Kamel
773	0		_x0019-5464 _tIndian journal of pharmaceutical education and research _dBengluru Association of Pharmaceutical Teachers of India (APTI)
856			_uhttps://www.ijper.org/sites/default/files/IndJPhaEdRes-55-4-1066.pdf _yClick here
942			_2ddc _cAR